This past April, our founder Virgil Stenberg had the opportunity to speak at the prestigious Global Pharmaceutical Congress in Singapore. There, he shared his positive results regarding treatment for patients suffering from rheumatoid arthritis.
As part of our Microdose Therapy™, we provide micro amounts of cortisone to help our patients fight off their symptoms. At the Global Pharmaceutical conference, we discussed a study where rheumatoid arthritis patients were taught to take cortisone tablets only on their bad days. Further, they were instructed not to take it on their good days where they weren’t feeling the effects of their symptoms.
So, what was the purpose of this instruction? Ultimately, no one knows their body better than patients do, and we thought they would be more efficient at using cortisone than the doctors who prescribe daily are. By using such a miniscule amount of cortisone, we hoped that the medication’s prohibitive side effects would be avoided.
The results were fascinating. Eighteen people in the double-blind study achieved an average of 75% improvement with no significant side effects. This was notable because that number showed it was twice as effective as other modern treatments.
Helen Foundation Study
Due to the positive result, the Helen Foundation proudly sponsored an open study with 2, 015 patients, and it included 36 other cortisone-responding diseases. In that study, we 76% of our respondents reported no significant side effects. The second study included the following diseases:
- 601 cases of fibromyalgia
- 579 cases of osteoarthritis
- 246 cases of rheumatoid arthritis
- 51 cases of Parkinson’s disease
- 25 cases of dementia
- 19 cases of multiple sclerosis
- 11 cases of asthma
Ultimately, having patients administer their own cortisone is likely the breakthrough we need to solve these terrible diseases.
The Helen Foundation is proud to be a leader in finding solutions for patients with these awful diseases. To learn more about Microdose Therapy™ or to further discuss our findings, contact us.